Benefit And Risk Of Endomyocardial Biopsy For Heart Transplant Patients In The Contemporary Era

Vincenzo Cusi,Nicholas Rodgers,Nicholas Wettersten,Florin Vaida,Yuko Tada,Bryn Gerding,Barry Greenberg,Eric Adler,Paul Kim

DOI: https://doi.org/10.1016/j.cardfail.2023.10.314

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction The reference standard of detecting acute rejection (AR) in heart transplant (HTx) patients is an endomyocardial biopsy (EMB). The majority of EMBs are performed by protocol in asymptomatic patients (surveillance EMB). However, immunosuppression regimens have improved to significantly reduce AR in the past decade. In this study, we evaluated the benefit:risk of surveillance versus for cause (driven by signs/symptoms concerning for AR) EMBs in the contemporary era. Hypothesis We hypothesize that the benefit:risk of for cause EMBs will be significantly higher than surveillance EMBs. Methods We retrospectively analyzed 2,757 consecutive EMBs obtained in 325 HTx patients between 2019 and 2022. Variables collected include recipient and donor characteristics, EMB procedural data, EMB pathologic grades, treatment for AR, and clinical outcomes. EMB complications were determined on chart review by two HTx cardiologists, with a third cardiologist adjudicating any discrepancies. Poisson models were used to evaluate the benefit:risk in the for cause compared to surveillance groups via an interaction term. Results The overall EMB complication rate was low at 1.5%, with no complication directly leading to death. Time from HTx showed an inverse relationship with EMB complications that was significant (OR = 0.04 per month, pc = 0.008). The overall treated AR rate was also low (3.5%). In the for cause EMB group, the treated AR rate increased to 14.0%. In the surveillance EMB group, the treated AR rate decreased to 1.5%. Thus, we found the benefit:risk was significantly higher in the for cause compared to the surveillance EMB group (22.3 vs 0.8, p < 0.001). Conclusions For cause EMBs show significantly higher benefit:risk compared to surveillance EMBs due to significantly reduced rates of detected treated AR in surveillance EMBs. The benefit:risk of surveillance EMBs should be continually reassessed as AR rates decrease with improving medical therapy.

cardiac & cardiovascular systems